Breaking New Ground in Biologic Medicine Production

In a landmark move, Regeneron Pharmaceuticals Inc. has inked a monumental $3 billion deal with Fujifilm Diosynth Biotechnologies. This partnership is set to amplify the production and supply of Regeneron's commercial biologic medicines at Fujifilm's North Carolina campus, marking a significant leap forward in the pharmaceutical industry.

A Commitment to Excellence and Growth

"Our collaboration with Fujifilm is a testament to our unwavering commitment to quality and innovation," stated Daniel Van Plew, Regeneron's Executive Vice President. The alliance not only underscores Regeneron's high standards but also Fujifilm's capacity to meet and exceed these expectations, with operations already underway at the Holly Springs facility.

Investing in the Future

Beyond this partnership, Regeneron is channeling over $7 billion into enhancing its production and infrastructure across New York and North Carolina, signaling a robust investment in the future of healthcare and medicine.